Havish Thatavarthi, Founder at MathMinds, shared a post on LinkedIn:
“In modern oncology, precision and advanced cellular therapies are changing everything.
This MedNews Week | OncoDaily lecture features Dr. Lekha Mikkilineni, whose discussion highlights how innovation in next-generation CAR T-cell platforms is reshaping treatment strategies for multiple myeloma.
A few key takeaways:
- Dual-targeting and engineered precision are key to hitting cancer clones while sparing healthy tissues
- Expertly managing unique toxicity profiles allows clinicians to safely maintain treatment effectiveness
- Moving advanced cellular immunotherapies into earlier lines of care helps stay ahead of tumor resistance
Definitely worth watching for anyone interested in cellular therapy, multiple myeloma research, and the future of precision cancer care.”
Other articles on OncoDaily.